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Epigallocatechin-3-gallate (EGCG) is a type of catechin extracted from green tea, which is reported to
have anticancer effects. EGCG is also reported to inhibit the cancer stem/progenitor cells in several es-
trogen receptor (ER)-negative breast cancer cell lines, such as SUM-149, SUM-190 and MDA-MB-231. And
all these cancer cells are highly expressed a new variant of ER-a, ER-a36. The aim of our present study is
to determine the role of ER-a36 in the growth inhibitory activity of EGCG towards ER-negative breast
cancer MDA-MB-231 and MDA-MB-436 cells. We found that EGCG potently inhibited the growth of
cancer stem/progenitor cells in MDA-MB-231 and MDA-MB-436 cells, and also reduced the expression of
ER-a36 in these cells. However, in ER-a36 knocked-down MDA-MB-231 and MDA-MB-436 cells, no
signiﬁcant inhibitory effects of EGCG on cancer stem/progenitor cells were observed. We also found that
down-regulation of ER-a36 expression was in accordance with down-regulation of EGFR, which further
veriﬁed a loop between ER-a36 and EGFR. Thus, our study indicated ER-a36 is involved in EGCG's
inhibitory effects on ER-negative breast cancer stem/progenitor cells, which supports future preclinical
and clinical evaluation of EGCG as a therapeutic option for ER-a36 positive breast cancer.
© 2015 Japanese Pharmacological Society. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Breast cancer is one of the most commonly diagnosed cancers in
women (1). Based on the presence or the absence of the speciﬁc
estrogen receptor (ER), ER-a, human breast cancers can be divided
into the ER-positive and -negative subtypes (2). While ER-positive
breast cancers are often treated with ER antagonists, such as ful-
vestrant/tamoxifen and aromatase inhibitors, ER-negative tumors
are unresponsive to endocrine-targeted therapy and are mostly
treated with chemotherapy (3, 4). Considering the severe toxicity,
side effects and poor response rate associated with chemotherapy,
less toxic and more effective therapeutic agents are needed for the
treatment of human ER-negative breast cancer.2946565@qq.com (B. Zhao),
63.com (S. Han), wml@sdu.
rmacological Society.
aternal and Child Health Care
. Production and hosting by ElseAccumulating evidence indicated that a subpopulation of tumor
cells, characterized with distinctive stem/progenitor properties, is
responsible for tumor initiation, invasive growth, andmetastasis (5,
6). These tumor-initiating or cancer stem/progenitor cells are
capable of self-renewal and differentiation, resulting in the vast
majority of the tumor bulk cells (7, 8). As cancer stem/progenitor
cells are resistant to most conventional therapy, including chemo-
therapy and radiation therapy, novel and effective agents that
speciﬁcally target these cells are urgently needed.
In 2006,Wang et al. identiﬁed and cloned a 36 kDa variant of ER-
a, ER-a36 (9, 10). Unlike conventional ER-a and ER-b, ER-a36 is
mainly expressed at the plasma membrane and in the cytoplasm,
andmediates non-genomic estrogen signaling, including activation
of the ERK1/2 and PI3K/AKT pathways (11, 12). Previous studies
have revealed that ER-a36 expressionwas detected in breast cancer
patients diagnosed as ER-negative (absence of ER-a66 expression)
(11). ER-a36 is also over-expressed in ER-negative breast cancer cell
lines, which is associated with the malignant growth of cancer cells
(13). It has been veriﬁed that there exists an ER-36/EGFR cross-
regulatory loop in which EGFR and ER-a36 positively regulate each
other's expression (13). Recently, ER-a36 expression was reportedvier B.V. This is an open access article under the CC BY-NC-ND license (http://
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stem/progenitor cells, in clinical samples of breast cancer patients
(14). Additionally, in SK-BR-3, an ER-negative breast cancer cell line,
knockdown of ER-a36 resulted in a decrease of the ALDH1-positive
cells (15). Thus, ER-a36 may play an important role in maintenance
and expansion of cancer stem/progenitor cells, and also presents an
attractive target for cancer stem cell-targeted therapy.
Epigallocatechin-3-gallate (EGCG), the most abundant and
active constituent in green tea, has therapeutic beneﬁts for a variety
of pathological conditions, including cancer, neurodegenerative
diseases, diabetes, and cardiovascular diseases (16). EGCG affects
several signaling and metabolic pathways, leading to the inhibition
of cancer cell growth, and tumor angiogenesis (17e19). Previous
studies have shown that EGCG treatment inhibits ER-negative tu-
mor growth (20, 21), and also inhibits growth of ER-negative breast
cancer stem/progenitor cells (22). Recently, Chung et al. reported
that the EGCG is more potent in ER-negative breast cancer MDA-
MB-231 cells compared to ER-positive MCF7 cells (23). Thus, EGCG
is potent growth inhibitor of malignant growth of ER-negative
breast cancer cells. However, the mechanism by which EGCG me-
diates inhibition of the growth of ER-negative breast cancer stem/
progenitor cells is not clear.
Previously, an ER-a36 speciﬁc down-regulator, Broussoﬂavonol
B, a chemical puriﬁed from the bark of the Paper Mulberry tree, is
reported to restrict the growth of ER-negative breast cancer stem/
progenitor cells (24). Both EGCG and Broussoﬂavonol are phenolic
compounds extracted from plants, and both have a ﬂavonoid
backbone (25). Since Broussoﬂavonol B shares a similar chemical
structure with EGCG (Fig. 1), we decided to study whether EGCG
functions through the ER-a36 signaling pathway.
2. Materials and methods
2.1. Chemicals and reagents
EGCG (95% pure) was obtained from SigmaeAldrich (St Louis,
MO, USA). EGFR antibody was purchased from Cell Signaling
Technology (Danvers, MA, USA). The monoclonal anti-ER-a36
antibody and ER-a36-speciﬁc shRNA expression vector were kindly
provided by Dr. Zhao-Yi Wang (Department of Medical Microbi-
ology& Immunology, Creighton University Medical School, Omaha,
Nebraska, USA). b-actin antibody was purchased from Santa Cruz
Biotechnology (Santa Cruz, CA, USA). PerCP-Cy™ 5.5 mouse anti-
human CD44 and PE mouse anti-human CD24 antibodies were
obtained from BD Biosciences (San Jose, CA, USA). Dulbecco'sFig. 1. Chemical structures of EGCG and Broussoﬂavonol B. (A). EGCG. (B). Broussoﬂavono
shape ring, respectively.Modiﬁed Eagle's Medium/Nutrient Mixture F-12 (DMEM/F12), fetal
bovine serum (FBS) and B27 were purchased from Invitrogen
(Carlsbad, CA, USA).
2.2. Cell culture and treatment
MDA-MB-231 and MDA-MB-436 cells were purchased from the
American Type Culture Collection (ATCC, Manassas, VA, USA) and
cultured in Dulbecco's modiﬁed Eagle's medium (DMEM) supple-
mented with 10% heat-inactivated fetal bovine serum (FBS), 0.05 U/
mL penicillin and 0.05 mg/mL streptomycin. Cells were maintained
in phenol red-free media with 2.5% charcoal-stripped FBS (Thermo
Scientiﬁc Hyclone, Logan, UT, USA) for 24 h prior to experimenta-
tion. All cell cultures were maintained at 37 C with 5% CO2 in a
humidiﬁed incubator. Using a FACSCalibur ﬂow cytometer (BD
Biosciences, San Jose, CA, USA), the CD44þ/CD24 cell population
was examined following incubation with PerCP mouse anti-human
CD44 and PE mouse anti-human CD24 antibodies as per the man-
ufacturer's instructions.
2.3. Tumorsphere formation assay and ﬂow cytometry analysis
To evaluate the growth of cancer stem/progenitor cells, single
cell suspensions of 5  104 MDA-MB-231 or MDA-MB-436 cells
were seeded into low attachment 6-well dishes (Corning Incorpo-
rated, Corning, NY, USA) and cultured in the tumorsphere medium
containing indicated concentrations of EGCG. The typical tumor-
sphere media are phenol-red free DMEM/F12 medium supple-
mented with 1  B27, 20 ng/ml epidermal growth factor
(SigmaeAldrich, St. Louis, MO, USA), 20 ng/ml basic ﬁbroblast
growth factor (ProSpec, NJ, USA), and 0.5 mg/ml hydrocortisone
(Sigma Aldrich Co., St. Louis, MO, USA). After seven days of culture
with the indicated concentrations of EGCG, the number of tumor-
spheres and dissociated cells were counted, as previously described
(13). Three dishes were used for each concentration tested, and all
of the experiments were conducted in triplicate.
For analysis of the CD44þ/CD24 cell population, single cell
suspensions were washed with cold PBS containing 1% BSA and
then incubated for 30 min at 4 C with PerCP-CyTM5.5 mouse
anti-human CD44 and PE mouse anti-human CD24 in PBS con-
taining 1% BSA. After incubation, cells were washed twice and re-
suspended in cold PBS containing 1% BSA for ﬂow cytometry
analysis. For the EGF-stimulated growth assay, EGF (10 ng/ml),
EGCG (20 mM or 30 mM) or both EGF and EGCG were added to cell
cultures and incubated for 72 h. Total cell counts werel B. The core structure shared by EGCG and Broussoﬂavonol B was marked with an oval-
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each treatment, and all experiments were replicated more than
three times.2.4. Cell transfection and establishment of stable cell lines
To establish cell lines with ER-a36 expression knocked down by
the shRNA method in breast cancer cells, stable cell lines were
established as described previously (26). Brieﬂy, cells transfected
with the empty expression vector or the ER-a36-speciﬁc shRNA
expression vector were selected in medium containing 300 mg/ml
G418 for 3 weeks, and more than 20 individual clones of selected
cells were pooled and were named as MB-231/shV or MB-436/shV
and MB-231/sh36 or MB-436/sh36. The knocked-down level of ER-
a36 expression was conﬁrmed by Western blot analysis.2.5. Western blot analysis
Western blot analysis was performed following the standard
protocol. Brieﬂy, cells were lysed, and the BCA assay was used to
determine protein concentration of cell lysates. Protein samples
were separated on a 10% gel using sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE). Proteins were
then electro-transferred onto a PVDF membrane. The membranes
were probed with appropriate primary antibodies followed by in-
cubationwith horseradish peroxidase (HRP)-conjugated secondary
antibodies. Bands were visualized using an enhanced chem-
iluminescence (ECL) system. Data within a linear range was quan-
tiﬁed using ImageQuant software (GE Amersham, Piscataway, NJ,
USA).2.6. Statistical analysis
Data were summarized as the mean ± standard error (SE) using
the GraphPad InStat software program. TukeyeKramer Multiple
Comparisons Test was also used, and the signiﬁcance was accepted
for P < 0.05.3. Results
3.1. EGCG inhibits the growth of breast cancer stem/progenitor cells
derived from ER-negative breast cancer cells
We tested the effects of EGCG on MDA-MB-231 and MDA-MB-
436 tumorsphere cells. MDA-MB-231 and MDA-MB-436 cells
were cultured in tumorsphere medium and in ultra-low attach-
ment dishes. After seven days of treatment, total tumorsphere
number and the cell number of dissociated tumorspheres were
counted, respectively. We found that EGCG effectively inhibited the
growth of tumorsphere cells from these two cell lines (Fig. 2A, B).
The CD44þ/CD24 characteristic is often used to identify and
characterize breast cancer stem cells. To test the effect of EGCG on
breast cancer stem/progenitor cells, we tested the effect of EGCG
treatment on the CD44þ/CD24 population in MDA-MB-231 and
MDA-MB-436. We treated MDA-MB-231 and MDA-MB-436 cells
with EGCG (20 mM) for seven days, and then we analyzed the
CD44þ/CD24 population with ﬂow cytometry. We found that
EGCG treatment signiﬁcantly reduced the CD44þ/CD24 cell pop-
ulation in these cells (Fig. 2C, D). These results indicated that EGCG
effectively inhibited the growth of ER-negative breast cancer stem/
progenitor cells.3.2. EGCG down-regulates ER-a36 expression in ER-negative breast
cancer cells
Previous studies indicated that ER-a36 is highly expressed in ER-
negative breast cancer cells such as MDA-MB-231 and MDA-MB-
436 cells (13) and is critical for the maintenance of stem/progenitor
cells in both ER-positive and ER-negative breast cancer cells (14,
15). In the ER-negative breast cancer cell lines MDA-MB-231 and
SK-BR-3, down-regulation of ER-a36 expression signiﬁcantly
reduced ALDH1-positive cell population (27). To probe the mech-
anism by which EGCG inhibited the growth of ER-negative cancer
stem/progenitor cells, we decided to determine whether EGCG also
down-regulated ER-a36 expression. Western blot analysis indi-
cated that ER-a36 expression was down-regulated by EGCG treat-
ment in a dose-dependent manner in MDA-MB-231 and MDA-MB-
436 cells (Fig. 3A and B). Thus, our data indicated that down-
regulation of ER-a36 expression is involved in growth inhibition
of ER-negative breast cancer cells by EGCG.
3.3. EGCG also down-regulates EGFR expression and inhibits EGF-
stimulated cell proliferation
Recently, Zhang et al. reported that there exists an ER-a36/EGFR
positive feedback loop in ER-negative breast cancer cells; ER-a36
knockdown resulted in destabilization of EGFR protein (13). We
decided to investigate whether EGCG-mediated down-regulation
of ER-a36 expression also results in decreased EGFR expression.
Accordingly, we examined EGFR expression in MDA-MB-231 and
MDA-MB-436 following EGCG treatment. We found that EGCG
treatment down-regulated EGFR expression in the two cell lines
(Fig. 4A and B).
MDA-MB-231 and MDA-MB-436 breast cancer cell lines are
characterized by the absence of estrogen receptor, progesterone
receptor and HER2 expression and thus are named triple-negative
breast cancer. As such, EGFR signaling is critical for the malignant
growth of triple-negative breast cancer. As EGCG treatment down-
regulated EGFR expression, we decided to examine the effect of
EGCG treatment following EGF stimulation in MDA-MB-231 and
MDA-MB-436 cells. As shown in Fig. 4C and D, under serum-
starvation conditions, cell proliferation was stimulated by the
addition of EGF. However, EGF-stimulated cell proliferation was
inhibited by EGCG, indicating that EGCG attenuates EGF signaling
possibly through the inhibition of EGFR expression. We then
examined the time course of the inhibition of EGFR expression by
ER-a36 knockdown. MDA-MB-231 and MDA-MB-436 cells were
treated with 40 mM of EGCG and the expression levels of EGFR and
ER-a36 were examined at 12, 24, 48, or 72 h. As shown in Fig. 4E,
EGCG treatment was able to down-regulate ER-a36 expression at
24 h, which lasted for 72 h in MDA-MB-231 cells. EGFR expression
began to be down-regulatedwithin 48 h (Fig. 4E). We also observed
similar change of EGFR expression in MDA-MD-436 cells, which
lagged behind the down-regulation of ER-a36 expression (Fig. 4F).
Thus, our results strongly suggested that ER-a36-mediated
signaling is involved in the modulation of EGFR expression.
3.4. EGCG inhibited the MAPK/ERK and the PI3K/AKT signaling in
breast cancer cells
Previous studies demonstrated that ER-a36 expression is closely
related to the activation of theMAPK/ERK signaling in breast cancer
(13). Several reports indicated that the MAPK/ERK and the PI3K/
AKT signaling are the major non-genomic estrogen signaling
pathways mediated by ER-a36, and both of the two signaling
pathways are also involved in the positive feedback loop of ER-a36/
EGFR (28e31). It has been reported EGCG treatment caused an
Fig. 2. EGCG reduces populations of the cancer stem/progenitor cells from ER-negative MDA-MB-231 and MDA-MB-436 cells. The tumorsphere formation assay and ﬂow
cytometry analysis of the CD44þ/CD24 cells were used to assess the population of breast cancer stem/progenitor cells. A and B, EGCG treatment decreases the number of
tumorspheres and cells from dissociated tumorspheres derived from MDA-MB-231 cells (A) and MDA-MB-436 cells (B). C and D, EGCG treatment decreased the population of the
CD44þ/CD24 cells in MDA-MB-231 and MDA-MB-436 cells. The MDA-MB-231 and MDA-MB-436 cells were treated with vehicle (DMSO) or indicated concentrations of EGCG for
seven days. The CD44þ/CD24 population cells were analyzed after staining with ﬂuorochrome-conjugated antibodies. C, The representative results are shown. D, The columns
represent the means of three experiments; bars, SE. *P < 0.05 for control cells treated with vehicle DMSO.
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and AKT in MDA-MB-231 cells (32). To further test the possibility
that EGCG may inhibit the MAPK/ERK and PI3K/AKT signaling, we
examined the phosphorylated ERK and AKT in MDA-MB-436 cells
treated with EGCG. The results showed that the phosphorylation
level of the ERK1/2 was down-regulated by 20e40 mM EGCG in a
dose-dependent manner (Fig. 5A). As showed in Fig. 5B, the PI3K/
AKT signaling was also attenuated by EGCG in a dose-dependent
manner. These results suggested that EGCG activity in suppres-
sion of the MAPK/ERK and the PI3K/AKT signaling pathways is
involved in down-regulation of ER-a36 expression in breast cancer
cells.3.5. ER-a36 knockdown reduced the sensitivity of the breast cancer
cells to EGCG
To further determine the role of ER-a36 in EGCG's effects on
breast cancer stem/progenitor cells, we established two stable ER-
a36 knockdown cell lines, MB-231/sh36 and MB-436/sh36. The ER-
a36 expression in MB-231/sh36 and MB-436/sh36 with ER-a36expression knocked downwas dramatically decreased compared to
the control cells transfected with the empty expression vector
(Fig. 6A). We next examined the effect of ER-a36 knockdown on
EGCG inhibitory activity in breast cancer stem/progenitor cells. As
shown in Fig. 6B, MB-231/sh36 exhibited dramatically decreased
sensitivity to EGCG compared to the control cells transfected with
empty vectors. Similarly, MB-436/sh36 cells with ER-a36 knock-
down were also less sensitive to EGCG than control MB-436/shV
cells (Fig. 6C).4. Discussion
In this study, we investigated the growth inhibitory potential of
EGCG in ER-negative breast cancer stem/progenitor cells. We
demonstrated that EGCG potently inhibited the growth of MDA-
MB-231 and MDA-MB-436 stem/progenitor cells presumably
through down-regulation of ER-a36 and EGFR expression.
A recent study indicated that the combination of curcumin and
EGCG inhibited the growth of the cancer stem/progenitor cells from
ER-negative breast cancer MDA-MB-231 cells (23) while EGCG
Fig. 3. EGCG treatment down-regulates ER-a36 expression in ER-negative MDA-MB-231 and MDA-MB-436 cells. Cells maintained in phenol red-free medium with 2.5%
charcoal-stripped fetal calf serum were treated with vehicle DMSO and the indicated concentrations of EGCG for 24 h. Western blot analysis was performed to examine the
expression of ER-a36 in MDA-MB-231 cells (A) and MDA-MB-436 cells (B). All membranes were stripped and re-probed with b-Actin antibody to ensure equal loading. The columns
represent the means of three experiments; bars, SE. *P < 0.05 for control cells treated with vehicle DMSO.
X. Pan et al. / Journal of Pharmacological Sciences 130 (2016) 85e93 89alone was without any effect. Our results, however, indicated that
EGCG alone effectively inhibited growth of ER-negative breast
cancer stem/progenitor cells. The exact mechanism underlying this
discrepancy is not clear. One possibility is that different concen-
trations of EGCG were used. They used 10 mM EGCG in their study,
however, we failed to observe signiﬁcant inhibition in cancer stem/
progenitor cells with their dosage in our model.
As one of the most commonly consumed beverages worldwide,
green tea has become a subject of interest for its potential anti-
cancer properties. The most potent anti-cancer compound from
green tea, EGCG, has been shown to affect cell growth, apoptosis,
tumor angiogenesis and metastasis (33, 34). The molecular mech-
anisms underlying these anti-cancer properties are multiple facets,
including catechins-based antioxidant/pro-oxidant activity, enzyme
activity manipulation, and modulation of cancer-relevant molecular
targets or signaling pathways (32, 35, 36). Accumulating evidence
suggests thatmany cancersmay originate from a small population of
cancer stem/progenitor cells, which represent attractive new targets
for cancer therapy. Zhang et al. reported that EGCG treatment
inhibited cell viability and neurosphere formation aswell as induced
apoptosis of stem/progenitor cells in neuroblastoma U87 cells (37).
Recently, a study has shown a dose-dependent reduction of cancer
stem cell viability following EGCG treatment in human prostate
cancer cell lines (38). EGCG treatment has also been shown to inhibit
the proliferation of stem-like cells in inﬂammatory breast cancer
(22). Additionally, EGCG treatment reduced growth and induced
apoptosis of breast cancer stem/progenitor cells in culture (22) and
decrease the growth of tumors derived from ALDH-positive stem/
progenitor cells (22). Here, we reported that EGCG treatment
effectively inhibits the growth of tumorsphere cells and CD44þ/
CD24 cells from MDA-MB-231 and MDA-MB-436 cells, which
further veriﬁed that EGCG is able to inhibit the growth of ER-
negative breast cancer stem/progenitor cells.
Further investigation of the mechanism of tumor by which
EGCG inhibits growth of breast cancer stem/progenitor cells
revealed that EGCG treatment down-regulated ER-a36 expression
in MDA-MB-231 and MDA-MB-436 cells. ER-a36, a variant of ER-a,
is found to be highly expressed in ~40% of ER-negative breast cancer
(11). ER-a36 has also been reported tomediatemitogenic activity ofestrogen in ER-negative breast cancer MDA-MB-231 and MDA-MB-
436 cells, which lack ER-a66 expression (13). Recently, Deng et al.
reported that ER-positive breast cancer stem/progenitor cells ex-
press high levels of ER-a36 while shRNA-based knockdown of ER-
a36 expression signiﬁcantly reduced the percentage of breast
cancer stem/progenitor cells (39). In addition, Kang et al. reported
ER-a36 is critical in the maintenance of the ALDH1-positive cancer
stem/progenitor cells (15), suggesting that ER-a36 expression is
one characteristic of breast cancer stem/progenitor cells. Thus,
down-regulation of ER-a36 expression may provide a novel ther-
apeutic approach to treat ER-negative human breast cancer. Guo
et al. reported that treatment with Broussoﬂavonol B, an ER-a36
speciﬁc down-regulator, restricted the growth of the ER-negative
MDA-MB-231 and SK-BR-3 breast cancer cells (24). To further
determine the role of ER-a36 in EGCG-induced inhibition of breast
cancer stem/progenitor cells, two pairs of breast cancer cell lines,
MDA-MB-231/shV and MDA-MB-231/sh36 cells as well as MDA-
MB-436/shV and MDA-MB-436/sh36 cells, were used. ER-a36
knockdownwas found to decrease the sensitivity of MDA-MB-231/
sh36 and MDA-MB-436/sh36 cells to EGCG treatment, indicating
that ER-a36 is involved in EGCG-induced inhibition of breast cancer
stem/progenitor cells. Our study also indicated that the cells with
ER-a36 knockdown formed much less tumorsphere compared to
the control cells, suggesting that ER-a36 is involved in the main-
tenance of cancer stem/progenitor cells. In one of our previous
studies, we demonstrated that the MCF7-HER2/18 cells that highly
express ER-a36 formed more tumorspheres compared to the
parent MCF7 cells while ER-a36 knocked-down in MCF-HER2/
18 cells signiﬁcantly decreased tumorsphere number (40). Consis-
tent with our results, Zhang et al. reported that the MDA-MB-
231 cells with ER-a36 knockdown showed signiﬁcant reduction of
the tumor growth in a xenograft mouse model, compared to the
control MDA-MB-231 cells (31). Thus, both in vitro and in vivo
studies indicated ER-a36 plays a critical role in maintenance of
breast cancer stem/progenitor cells.
EGCG treatment has been suggested to exert different effects on
several signal pathways in breast cancer (41, 42). EGCG, with the
combination of raloxifene, has been revealed to inhibit the activa-
tion of the AKT, mammalian target of rapamycin (mTOR) and S-6-
Fig. 4. EGCG down-regulates EGFR expression and attenuated mitogenic EGF signaling in MDA-MB-231 and MDA-MB-436 cells. A and B, Cells were treated with indicated
concentrations of EGCG for 48 h. Cell lysates were subjected to Western blot analysis with an antibody for EGFR. The membrane was stripped and re-probed with a b-actin antibody
to ensure equal loading. C and D, Cells maintained in phenol red-free mediumwith 2.5% charcoal-stripped FBS for 48 h. EGF (10 ng/ml) alone, together with indicated concentrations
of EGCG or EGCG alone were added to cells and incubated for 72 h, and cell numbers were determined. Three dishes were used for each treatment and experiments were repeated
more than three times. E and F, MDA-MB-231 (E) and MDA-MB-436 (F) cells were treated with 40 mM EGCG for different time periods (12, 24, 48 and 72 h) andWestern blot analysis
was performed to examine the levels of EGFR and ER-a36 expression. Columns: means ± SEM from three independent experiments. *P < 0.05 versus control cells without
treatment; #P < 0.05 versus cells treated with EGF (10 ng/ml).
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negative breast cancer cells (35). Previous studies have also re-
ported thatMDA-MB-231 cells exposed to EGCG showed signiﬁcant
reduction in the NF-kB activation and the AKT phosphorylation (26,
36, 43). The MAPK/ERK pathway is one of the most important
intracellular signal transductions in breast cancer. EGCG has been
demonstrated to inhibit theMAPK/ERK activation and to reduce the
expression and activity of matrix metalloproteinase 9 (MMP-9) in
MDA-MB-231 cells (32). EGCG was also shown to repress the he-
patocyte growth factor (HGF)-induced AKT and ERK phosphoryla-
tion in ER-negative breast cancer cells (37), further indicating the
potent inhibitory activity of EGCG on the MAPK/ERK and PI3K/AKTpathways. Here, we found that EGCG attenuated the ERK and AKT
signaling in ER-negative MD-MBA-436 cells. It has been reported
that ER-a36 mediated the MAPK/ERK and the PI3K/AKT signal
transduction. Thus, our results suggested EGCG inhibits the growth
of ER-negative breast cancer cells through the repression of ER-
a36-mediated MAPK/ERK and PI3K/AKT signaling.
In our study, we also found that EGCG treatment resulted in
reduced EGFR expression, and cells treated with EGCG reacted
poorly to EGF stimulation. Thus, EGCG treatment also attenuates
EGF signaling in ER-negative breast cancer cells. Previous studies
have reported that EGCG inhibits the EGFR signaling presumably
through the inhibition of the ERK1/2 and AKT kinases (44). It has
Fig. 5. EGCG inhibits the MAPK/ERK and PI3K/AKT signaling in breast cancer cells. A and B. MDA-MB-436 cells were treated with different concentrations of EGCG for 24 h.
Western blot analysis was performed to examine the levels of the phospho-ERK1/2 (A) and phospho-AKT (B). The phosphorylation levels of these proteins were normalized with the
expression levels of the total protein. Columns: means ± SEM from three independent experiments. *P < 0.05 versus control cells without treatment.
X. Pan et al. / Journal of Pharmacological Sciences 130 (2016) 85e93 91been conﬁrmed that a positive feedback loop of EGFR and ER-a36
expression is critical for malignant growth of ER-negative breast
cancer cells, in which ER-a36 mediates non-genomic estrogen
signaling and stabilizes EGFR protein while EGF signaling up-
regulates ER-a36 promoter activity through an Ap-1 binding site
in the promoter region (13). In our study, we also noted that EGFR
expression was inhibited by EGCG treatment, which lagged behind
the down-regulation of ER-a36 expression. Thus, our results
demonstrated that EGCG attenuates the EGF signaling presumably
through down-regulation of the positive loop between ER-a36 and
EGFR expression.Fig. 6. ER-a36 knockdown desensitizes breast cancer cells to EGCG treatment. A. ER-a36
and MB-436/sh36 cells using Western blot assays. B and C. The tumorspheres of MB-231/shV
or indicated concentrations of EGCG for seven days, and the cell numbers in tumorspheres w
for control cells treated with vehicle DMSO. #P < 0.05 for cells treated with EGF (10 ng/mlThe function and underlying mechanism of ER-a36 in ER-
negative breast cancer cells have been reported. The expression
proﬁles and function of ER-a36 in ER-positive cells have not been
well established. Wang et al. ﬁrst reported that the expression of
ER-a36 in ER-positive MCF7 cells and T47D cells (10). Chaudhri
et al. has reported the high level of ER-a36 expression in ER-
positive MCF7 cells (45), while Deng et al. found MCF7 cells
expressed very low level of endogenous ER-a36 (39). Zhang et al.
found the high-passage (>75 passages) MCF7 cells expressed high
level of ER-a36 as well as EGFR and HER2. However, ER-a36
expression in low-passage (<35 passages) MCF7 cells was very lowand EGFR expression levels were measured in MB-231/shV, MB-231/sh36, MB-436/shV
, MB-231/sh36, MB-436/shV and MB-436/sh36 cells were treated with vehicle (DMSO)
ere counted. The columns represent the means of three experiments; bars, SE. *P < 0.05
) alone.
X. Pan et al. / Journal of Pharmacological Sciences 130 (2016) 85e9392(28). They also observed enhanced ER-a36 expression in cells
cultured in high density and fresh serum (28). Thus, different MCF-
7 sub-lines as well as different culture conditions used in different
lab may lead to variable results concerning ER-a36 expression. In
our study, we found that consistent with the previous report (28),
EGCG showed little growth inhibitory activity in ER-a36 knock-
down cells, which suggested the growth inhibitory activity of EGCG
depends on ER-a36 expression.
In summary, EGCG potently inhibits the growth of ER-negative
stem/progenitor cells, presumably through down-regulation of
the ER-a36 and EGFR positive regulatory loop. EGCG is an effective
inhibitor of breast cancer proliferation and speciﬁc targets stem/
progenitor cells in ER-negative breast cancer. Our results also pro-
vided evidence to support the view to develop ER-a36 as a thera-
peutic target for breast cancer.
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